This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

13 Biotech Stocks Presenting New Clinical Data

Celldex Therapeutics (CLDX - Get Report)

Drug: CDX-110 (PF-04948568)

Abstract No.2014

Indication: Glioblastoma (brain tumor)

Clinical Trial: Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide in patients with glioblastoma (GBM).

Presentation Time: Saturday, June 5. Poster session.

Notes: Celldex's CDX-110, partnered with Pfizer, is engineered to activate a patient's immune system to fight cancer. Interest in so-called cancer "vaccines" is increasing as Dendreon (DNDN) awaits FDA approval of its prostate cancer immunotherapy Provenge. Celldex shares are running strong into the ASCO meeting, up 60% since February.

2 of 14

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
NKTR $11.37 -0.96%
PCYC $255.40 0.35%
SNSS $2.32 2.70%
ZIOP $9.84 3.40%
ARQL $2.08 -0.24%

Markets

DOW 18,098.29 +74.23 0.41%
S&P 500 2,117.34 +9.05 0.43%
NASDAQ 5,028.9360 +23.5450 0.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs